{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:17:33Z","timestamp":1792081053311,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ctrv.2025.102891","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T17:40:30Z","timestamp":1737913230000},"page":"102891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Melanoma-associated antigen A4: A cancer\/testis antigen as a target for adoptive T-cell receptor T-cell therapy"],"prefix":"10.1016","volume":"134","author":[{"given":"Gabrielle","family":"Knafler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Navenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102891_b0005","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2025.102891_b0010","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.4049\/jimmunol.172.10.6057","article-title":"T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product","volume":"172","author":"Huang","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2025.102891_b0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovi\u0107","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2025.102891_b0020","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/humrep\/del494","article-title":"MAGE-A1, GAGE and NY-ESO-1 cancer\/testis antigen expression during human gonadal development","volume":"22","author":"Gjerstorff","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ctrv.2025.102891_b0025","first-page":"15","article-title":"Expression of cancer-testis (CT) antigens in placenta","volume":"7","author":"Jungbluth","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1016\/j.ctrv.2025.102891_b0030","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2025.102891_b0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0040","doi-asserted-by":"crossref","first-page":"20422","DOI":"10.1073\/pnas.0810777105","article-title":"Genome-wide analysis of cancer\/testis gene expression","volume":"105","author":"Hofmann","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2025.102891_b0045","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/jcb.23252","article-title":"A majority of the cancer\/testis antigens are intrinsically disordered proteins","volume":"112","author":"Rajagopalan","year":"2011","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2025.102891_b0050","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.24296","article-title":"Cancer\/testis antigen CT45: analysis of mRNA and protein expression in human cancer","volume":"124","author":"Chen","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0055","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-04-0819","article-title":"NY-ESO-1 expression and immunogenicity in esophageal cancer","volume":"10","author":"Fujita","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0060","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/1878-0261.13474","article-title":"Expression of cancer\u2013testis antigens in the immune microenvironment of non-small cell lung cancer","volume":"17","author":"Hikmet","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0065","article-title":"Multiple cancer\/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102891_b0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/2326-6066.CIR-13-0088","article-title":"Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers","volume":"2","author":"Yao","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0075","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N","article-title":"Expression of MAGE-antigens in normal tissues and cancer","volume":"85","author":"Jungbluth","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0080","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.1282","article-title":"Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues","volume":"92","author":"Jungbluth","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0085","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1054\/bjoc.2000.1291","article-title":"Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours","volume":"83","author":"Jungbluth","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0090","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1002\/cncr.27446","article-title":"NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid\/round cell liposarcoma","volume":"118","author":"Pollack","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0095","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1128\/MCB.19.11.7327","article-title":"DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter","volume":"19","author":"De Smet","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2025.102891_b0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-2407-13-144","article-title":"Derepression of cancer\/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032165","article-title":"NYESO-1\/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine","volume":"7","author":"Pollack","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102891_b0110","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1158\/0008-5472.CAN-10-2442","article-title":"Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer","volume":"71","author":"Rao","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1158\/1541-7786.MCR-05-0229","article-title":"Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells","volume":"4","author":"Wischnewski","year":"2006","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/cells12060926","article-title":"Biology of cancer-testis antigens and their therapeutic implications in cancer","volume":"12","author":"Nin","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ctrv.2025.102891_b0125","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.95.12.6919","article-title":"Identification of multiple cancer\/testis antigens by allogeneic antibody screening of a melanoma cell line library","volume":"95","author":"Chen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2025.102891_b0130","first-page":"7","article-title":"The genealogy of SEREX","volume":"12","author":"Pfreundschuh","year":"2012","journal-title":"Cancer Immun"},{"key":"10.1016\/j.ctrv.2025.102891_b0135","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1073\/pnas.92.25.11810","article-title":"Human neoplasms elicit multiple specific immune responses in the autologous host","volume":"92","author":"Sahin","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2025.102891_b0140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.187.2.265","article-title":"Simultaneous humoral and cellular immune response against cancer\u2013testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2\u2013binding peptide epitopes","volume":"187","author":"J\u00e4ger","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2025.102891_b0145","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2131096","article-title":"Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients","volume":"11","author":"Noordam","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2025.102891_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ijo.2023.5519","article-title":"Cancer testis antigen subfamilies: attractive targets for therapeutic vaccine","volume":"62","author":"Ren","year":"2023","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12920-018-0354-x","article-title":"HLA and proteasome expression body map","volume":"11","author":"Boegel","year":"2018","journal-title":"BMC Med Genom"},{"key":"10.1016\/j.ctrv.2025.102891_b0160","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: a systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.102891_b0165","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0170","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0175","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1200\/JCO.2022.40.16_suppl.11500","article-title":"Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid\/round cell liposarcoma (MRCLS)","volume":"40","author":"D'Angelo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0180","first-page":"A1009","article-title":"959\u2005Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses \u2013 clinical update on the ACTengine\u00ae IMA203 trial","volume":"9","author":"Wermke","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0185","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1093\/oncolo\/oyad078","article-title":"Efficacy of T-cell receptor-based adoptive cell therapy in cutaneous melanoma: a meta-analysis","volume":"28","author":"Yarza","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.102891_b0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40264-018-0779-3","article-title":"Safety and tolerability of adoptive cell therapy in cancer","volume":"42","author":"Wolf","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctrv.2025.102891_b0195","series-title":"The EBMT\/EHA CAR-T Cell Handbook","article-title":"Management of immune effector cell-associated neurotoxicity syndrome (ICANS)","author":"Rees","year":"2022"},{"key":"10.1016\/j.ctrv.2025.102891_b0200","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2025.102891_b0205","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102891_b0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1\u2013presented peptide as a cross-reactive target for engineered MAGE A3\u2013directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2025.102891_b0215","first-page":"5544","article-title":"An overview of the MAGE gene family with the identification of all human members of the family","volume":"61","author":"Chomez","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148762","article-title":"Structures of two melanoma-associated antigens suggest allosteric regulation of effector binding","volume":"11","author":"Newman","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102891_b0225","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molcel.2010.08.029","article-title":"MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases","volume":"39","author":"Doyle","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2025.102891_b0230","doi-asserted-by":"crossref","first-page":"10668","DOI":"10.1074\/jbc.M206104200","article-title":"MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity","volume":"278","author":"Nagao","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2025.102891_b0235","doi-asserted-by":"crossref","first-page":"12105","DOI":"10.1038\/ncomms12105","article-title":"A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis","volume":"7","author":"Gao","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.102891_b0240","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s44318-024-00058-9","article-title":"Structural basis for RAD18 regulation by MAGEA4 and its implications for RING ubiquitin ligase binding by MAGE family proteins","volume":"43","author":"Griffith-Jones","year":"2024","journal-title":"EMBO J"},{"key":"10.1016\/j.ctrv.2025.102891_b0245","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3892\/or.2012.1934","article-title":"MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis","volume":"28","author":"Bhan","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2025.102891_b0250","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1158\/0008-5472.CAN-07-1478","article-title":"MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0255","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1021\/acs.jmedchem.2c00185","article-title":"Discovery and structural basis of the selectivity of potent cyclic peptide inhibitors of MAGE-A4","volume":"65","author":"Fleming","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2025.102891_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101265","article-title":"Identifying MAGE-A4-positive tumors for TCR Tcell therapies in HLA-A\u221702-eligible patients","volume":"32","author":"Wang","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ctrv.2025.102891_b0265","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-020-07098-4","article-title":"MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours","volume":"20","author":"Ishihara","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0270","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ijc.24503","article-title":"High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer","volume":"125","author":"Bergeron","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0275","first-page":"3937","article-title":"Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma","volume":"17","author":"Kakimoto","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2025.102891_b0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2004.07.028","article-title":"Expression of cancer\/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters","volume":"219","author":"Peng","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2025.102891_b0285","first-page":"6682","article-title":"MAGE-A gene expression pattern in primary breast cancer","volume":"61","author":"Otte","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0290","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bjophthalmol-2011-300432","article-title":"Expression of cancer-testis antigens (MAGE-A1, MAGE-A3\/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma","volume":"96","author":"Errington","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ctrv.2025.102891_b0295","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00428-017-2206-z","article-title":"MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1","volume":"471","author":"Iura","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2025.102891_b0300","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1007\/s00432-023-05274-0","article-title":"Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets","volume":"149","author":"Xiao","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0305","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.3390\/diagnostics13193092","article-title":"Characterization of cancer\/testis antigens as prognostic markers of ovarian cancer","volume":"13","author":"Vlasenkova","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2025.102891_b0310","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1158\/1078-0432.CCR-06-0527","article-title":"Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma","volume":"12","author":"Sharma","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104099","article-title":"Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer","volume":"9","author":"Daudi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102891_b0320","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2025.102891_b0325","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/diagnostics12030733","article-title":"Clinicopathological assessment of cancer\/testis antigens NY-ESO-1 and MAGE-A4 in highly aggressive soft tissue sarcomas","volume":"12","author":"Hashimoto","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2025.102891_b0330","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.10540","article-title":"Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study","volume":"100","author":"Kocher","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0335","first-page":"6453","article-title":"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms","volume":"9","author":"Yakirevich","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0340","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/ijc.25607","article-title":"Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma","volume":"128","author":"Cuffel","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0345","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41379-019-0253-5","article-title":"MAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformation","volume":"32","author":"Baran","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2025.102891_b0350","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage","volume":"12","author":"Barrow","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0355","first-page":"32","article-title":"Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study","volume":"47","author":"Bandi\u0107","year":"2006","journal-title":"Croat Med J"},{"key":"10.1016\/j.ctrv.2025.102891_b0360","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/lio2.160","article-title":"The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading","volume":"3","author":"Vital","year":"2018","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.ctrv.2025.102891_b0365","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00262-010-0916-z","article-title":"MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes","volume":"60","author":"Cesson","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2025.102891_b0370","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.gt.3303099","article-title":"Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) \u03b1\u03b2 genes transduced to CD8+ T cells","volume":"15","author":"Hiasa","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.ctrv.2025.102891_b0375","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2025.102891_b0380","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002035","article-title":"Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy","volume":"9","author":"Davari","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0385","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CJI.0000000000000456","article-title":"Enhancing efficacy of TCR-engineered CD4+ T cells via coexpression of CD8\u03b1","volume":"46","author":"Anderson","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2025.102891_b0390","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-019-1717-8","article-title":"T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2025.102891_b0395","unstructured":"Pope GR, Laycock-van Spyk S, Pachnio A, Adams K, Jefferson V, Cartwright N, et al. IL-7 and CCL19 expression in specific peptide enhanced affinity receptor T-cells targeting MAGE-A4 display improved survival and ability to induce migration of immune cells. Mol Ther. 2022;30:Abstract 385."},{"key":"10.1016\/j.ctrv.2025.102891_b0400","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0405","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.102891_b0410","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.102891_b0415","unstructured":"Moreno V, Calvo E, Asch A, Butler MO, Zugazagoitia J, Chalrson J, et al. Clinical and translational data from the phase 1 SURPASS trial of ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy alone or combined with nivolumab in solid tumors Presented at: ESMO Annual Meeting; October 23, 2023; Madrid, Spain."},{"key":"10.1016\/j.ctrv.2025.102891_b0420","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS708","article-title":"New phase 1 SURPASS trial cohort: early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma","volume":"42","author":"Aggen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0425","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.ijrobp.2024.01.187","article-title":"First-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in head and neck cancers: an additional cohort of the phase 1 SURPASS trial","volume":"118","author":"Ho","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2025.102891_b0430","doi-asserted-by":"crossref","unstructured":"Moore K, Oaknin A, Ray-Coquard I, Coleman RL, Herzog TJ, O\u2019malley D, et al. #24\u2005A phase 2 study (GOG-3084) of ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers. Int J Gynecol Cancer. 2023;33:A407\u20138. https:\/\/doi.org\/10.1136\/ijgc-2023-ESGO.866.","DOI":"10.1136\/ijgc-2023-ESGO.866"},{"key":"10.1016\/j.ctrv.2025.102891_b0435","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2006-03-013318","article-title":"Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex","volume":"109","author":"Heemskerk","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102891_b0440","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.1005802107","article-title":"Mixed T cell receptor dimers harbor potentially harmful neoreactivity","volume":"107","author":"van Loenen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2025.102891_b0445","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003811","article-title":"NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome","volume":"10","author":"Ishihara","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0450","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1158\/1078-0432.CCR-20-1523","article-title":"PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer","volume":"26","author":"Gray","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0455","first-page":"A424","article-title":"368\u2005Translational analyses reveal mechanisms of afami-cel\u2019s anti-tumor activity in synovial sarcoma","volume":"12","author":"Dupont","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.102891_b0460","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1007\/s00432-022-04514-z","article-title":"Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients","volume":"149","author":"Freiberger","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0465","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CMR.0000000000000869","article-title":"Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report","volume":"33","author":"He","year":"2023","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0470","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221107113","article-title":"Multi-antigen-targeted T-cell therapy to treat patients with relapsed\/refractory breast cancer","volume":"14","author":"Hoyos","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0475","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1159\/000533129","article-title":"Epstein Barr virus-positive lymphoproliferative disorder following lymphodepletion for MAGE A4 adoptive cellular therapy in a patient with synovial sarcoma: a case report","volume":"16","author":"Zhou","year":"2023","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0480","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1158\/1078-0432.CCR-20-0832","article-title":"HLA genotyping in synovial sarcoma: identifying HLA-A*02 and its association with clinical outcome","volume":"26","author":"Rosenbaum","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0485","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2006.02.004","article-title":"Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer","volume":"103","author":"Gamzatova","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0490","first-page":"2369","article-title":"HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer","volume":"34","author":"Tertipis","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0495","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","author":"Baulu","year":"202393700","journal-title":"Sci Adv"},{"key":"10.1016\/j.ctrv.2025.102891_b0500","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.102891_b0505","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2024-199551","article-title":"Preclinical proof of concept for decentralized manufacturing of a MAGE-A4\/CD8\u03b1-expressing autologous T-cell therapy for solid tumors","volume":"144","author":"Herman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102891_b0510","doi-asserted-by":"crossref","unstructured":"Blumenschein J, G. R., Davar D, Gutierrez R, Segal NH, Johnson ML, Dar MM, et al. A phase I\/II first-in-human study of a novel anti-MAGE-A4 TCR\/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101). J Clin Oncol. 2020;38:TPS3165. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS3165.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3165"},{"key":"10.1016\/j.ctrv.2025.102891_b0515","doi-asserted-by":"crossref","first-page":"S1411","DOI":"10.1016\/j.annonc.2021.10.109","article-title":"91P Phase I dose escalation of IMC-C103C, a CD3\u00d7MAGE-A4 T-cell receptor (TCR) bispecific protein","volume":"32","author":"Davar","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0520","doi-asserted-by":"crossref","unstructured":"Sweis R, Garralda E, Saavedra Santa Gadea O, Moore KN, Davar D, Hamid O, et al. 157P Phase I expansion of IMC-C103C, a MAGE-A4\u00d7CD3 ImmTAC bispecific protein, in ovarian carcinoma. Immunooncol Technol. 2022;16:100269. https:\/\/doi.org\/10.1016\/j.iotech.2022.100269.","DOI":"10.1016\/j.iotech.2022.100269"},{"key":"10.1016\/j.ctrv.2025.102891_b0525","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.annonc.2024.08.1060","article-title":"1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4\/8-directed half-life extended TCR bispecific, in phase I dose escalation","volume":"35","author":"Wermke","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102891_b0530","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1016\/j.vaccine.2014.09.002","article-title":"High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine","volume":"32","author":"Saito","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ctrv.2025.102891_b0535","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1111\/cas.15954","article-title":"T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease","volume":"114","author":"Okada","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2025.102891_b0540","doi-asserted-by":"crossref","first-page":"15134","DOI":"10.3390\/ijms242015134","article-title":"Exploring TCR-like CAR-engineered lymphocyte cytotoxicity against MAGE-A4","volume":"24","author":"Alsalloum","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.102891_b0545","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065109","article-title":"Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial","volume":"12","author":"Okumura","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctrv.2025.102891_b0550","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1538-7445.AM2024-1329","article-title":"Abstract 1329: Development of the first optimised \u201coff the shelf\u201d MAGE-A4 targeting TCR-NK cells for advancement into the clinic for the treatment of solid tumors","volume":"84","author":"Vollmers","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102891_b0555","article-title":"SURPASS-2 trial design: a phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers","author":"Hong","year":"202240363","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:26:46Z","timestamp":1762291606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":111,"alternative-id":["S0305737225000131"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102891","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melanoma-associated antigen A4: A cancer\/testis antigen as a target for adoptive T-cell receptor T-cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102891"}}